

F A C S I M I L E

Date: April 5, 2001

From: Harry B. Shubin

To: Examiner F. Higel
U.S. PATENT AND TRADEMARK
OFFICE
Group Art Unit 1626

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201 (U.S.A.)
(Fax: 703-243-6410)

Facsimile No.: (703) 308-7921

Writer's Direct Dial: (703) 812-5306

Telephone No.:

Writer's Internet Address: shubinh@mwzb.com


RE: U.S. Patent Application Serial No. 09/755,060
Attorney Docket No. BAYER-1 D1

Total No. of Pages: 18; if you do not receive all pages, please call 703-243-6333.

Dear Examiner Higel:

Attached is a copy of the Preliminary Amendment submitted in the above-referenced application on January 8, 2001. This copy is being provided at your request.

Very truly yours,


Nancy J. Robins
Secretary to Harry B. Shubin

HBS:njr
Attachment

K:\PAT\Bayer\1 D1\fax to Examiner 04.05.01.wpd

Information contained in this facsimile communication may contain privileged and confidential information and is intended solely for the use of the addressee listed above. If you are neither the designated recipient nor the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any disclosure, copying or distribution of, or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone on (703) 243-6333 to arrange for return of the original documents to us at our cost. Thank you.

310

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Box: PATENT APPLICATION

Jill E. WOOD et al.

Group Art Unit: 1626

Serial No.: Div. of 09/083,399

Examiner: F. Higel

Filed: December 14, 2000

For:

RAF KINASE INHIBITORS

*Placed
into
file
04/06/01*

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows prior to calculation of the fees.

B1

In the Claims:

Cancel claims 1 to ¹⁷~~18~~ without prejudice or disclaimer.

Amend the claims as follows:

see 1, 125

^R
-19. A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae:

